Literature DB >> 7545552

Increased soluble form of P-selectin in patients with unstable angina.

H Ikeda1, Y Takajo, K Ichiki, T Ueno, S Maki, T Noda, K Sugi, T Imaizumi.   

Abstract

BACKGROUND: P-selectin in platelets and endothelial cells mediates adhesive interaction with leukocytes to form thrombi. The purpose of the present study was to investigate the plasma levels of P-selectin in patients with unstable angina and in those with stable effort angina of different pathophysiologies. METHODS AND
RESULTS: Plasma P-selectin levels were determined by a monoclonal antibody-based enzyme immunoassay on plasma samples taken from 12 patients with unstable angina, 11 patients with stable effort angina, and 15 healthy volunteers. Patients with unstable angina had angina at rest associated with ECG changes. In patients with unstable angina, plasma P-selectin levels within 1 hour (361 +/- 90 ng/mL) and at 3 hours (282 +/- 56 ng/mL) after angina were significantly (P < .05) higher than those in volunteers (177 +/- 31 ng/mL). Plasma P-selectin levels at 5 hours after attack (242 +/- 46 ng/mL) did not differ from those in volunteers. Although patients with stable effort angina developed angina with ST-segment depressions by treadmill exercise, their plasma P-selectin levels did not change (before, 178 +/- 45; immediately after, 186 +/- 36; and 1 hour after the exercise, 179 +/- 34 ng/mL).
CONCLUSIONS: Plasma P-selectin levels after angina increased significantly in patients with unstable angina but did not in patients with stable effort angina. These findings may contribute to understanding of the pathophysiology of the acute coronary syndrome of unstable angina.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7545552     DOI: 10.1161/01.cir.92.7.1693

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  26 in total

Review 1.  Antiplatelet therapy in interventional cardiology: I. Newer oral antiplatelet agents.

Authors:  F H Jafary; C D Kimmelstiel
Journal:  J Thromb Thrombolysis       Date:  2000-02       Impact factor: 2.300

Review 2.  Inflammatory gene polymorphisms and ischaemic heart disease: review of population association studies.

Authors:  F Andreotti; I Porto; F Crea; A Maseri
Journal:  Heart       Date:  2002-02       Impact factor: 5.994

3.  Pro-coagulant state resulting from high levels of soluble P-selectin in blood.

Authors:  P André; D Hartwell; I Hrachovinová; S Saffaripour; D D Wagner
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

4.  P-selectin gene polymorphism associates with pulmonary hypertension in congenital heart disease.

Authors:  Xiao-Fei Li; Chun-Hui Song; Hong-Zhuan Sheng; Dong-Dong Zhen; Min Pan; Jian-Hua Zhu
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

Review 5.  Platelet reactivity and the identification of acute coronary syndromes in the emergency department.

Authors:  Chad E Darling; Alan D Michelson; Gregory A Volturo; Karin Przyklenk
Journal:  J Thromb Thrombolysis       Date:  2008-07-04       Impact factor: 2.300

6.  Patients with acute coronary syndromes express enhanced CD40 ligand/CD154 on platelets.

Authors:  C D Garlichs; S Eskafi; D Raaz; A Schmidt; J Ludwig; M Herrmann; L Klinghammer; W G Daniel; A Schmeisser
Journal:  Heart       Date:  2001-12       Impact factor: 5.994

Review 7.  Inflammation in acute coronary syndromes.

Authors:  N T Mulvihill; J B Foley
Journal:  Heart       Date:  2002-03       Impact factor: 5.994

Review 8.  Platelet activity and cardiovascular risk in apparently healthy individuals: a review of the data.

Authors:  Gaurav Sharma; Jeffrey S Berger
Journal:  J Thromb Thrombolysis       Date:  2011-08       Impact factor: 2.300

9.  Levels of soluble CD40 ligand and P-Selectin in nonalcoholic fatty liver disease.

Authors:  Cemal Nuri Ercin; Teoman Dogru; Serkan Tapan; Yildirim Karslioglu; Cem Haymana; Selim Kilic; Alper Sonmez; Zeki Yesilova; Ahmet Uygun; Mustafa Gulsen; Sait Bagci; M Kemal Erbil
Journal:  Dig Dis Sci       Date:  2009-05-14       Impact factor: 3.199

10.  Eptifibatide does not suppress the increase of inflammatory markers in patients with non-ST-segment elevation acute coronary syndrome.

Authors:  Alexey A Mazaev; Yaroslav A Naimushin; Valery P Masenko; Mikhail Y Ruda; Alexey V Mazurov
Journal:  J Thromb Thrombolysis       Date:  2007-12-28       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.